HDHuma Dar

Huma Dar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huma Dar has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up

    by Oscar Danielsson, Huma Dar, Anna Nordenskjöld, Gizeh Perez-Tenorio, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Nicholas P Tobin, Julia Tutzauer, Annelie Johansson, et al.

    Background: Patients with estrogen receptor–positive breast cancer have a substantial late risk of distant recurrence, but the long-term subtype-specific tamoxifen benefit remains poorly understood. Methods: A secondary analysis of the Stockholm Tamoxifen randomized trials (1976-1997, n = 3930) with 20-year follow-up was conducted. Formalin-fixed, paraffin-embedded blocks were available for 2250 patients. A total of 952 patients with estrogen receptor–positive and HER2-negative tumors, classified as luminal A (n = 688) and luminal B (n = 264) using Agilent microarrays, were analyzed. Patients were randomly assigned to at least 2 years of tamoxifen therapy or no endocrine therapy. Distant recurrence-free interval was assessed by Kaplan–Meier analysis and multivariable Cox proportional hazards regression. Results: Patients with luminal A tumors had low early risk and modest early benefit from tamoxifen therapy (5-year distant recurrence-free interval treated vs control: 93% vs 89%; absolute difference = 4%) that increased over the 20-year follow-up (20-year distant recurrence-free interval: 76% vs 66%; absolute difference = 10%), highlighting long-term benefit. In contrast, patients with luminal B tumors had larger early risk and treatment benefit (5-year distant recurrence-free interval: 72% vs 57%; absolute difference = 15%), which remained stable over time (20-year distant recurrence-free interval: 55% vs 37%; absolute difference = 18%). Multivariable analyses showed that luminal patients benefited from tamoxifen therapy (luminal A: adjusted hazard ratio [HR] = 0.57, 95% confidence interval [CI] = 0.42 to 0.78; luminal B: adjusted HR = 0.68, 95% CI = 0.46 to 0.99). Patients with favorable tumor characteristics benefited regardless of luminal subtype. Conclusions: Tamoxifen reduces the long-term risk of distant recurrence in luminal A and B tumors, although timing of benefit varies by subtype. Even after treatment, patients with luminal tumors have a substantial late risk, highlighting the need for long-term follow-up. Clinical Trial Registration: The trial center for the Stockholm Tamoxifen trials was the Regional Cancer Center Stockholm-Gotland, in Stockholm, Sweden. The start of the Stockholm Tamoxifen trials in 1976 was before the custom of trial registration started in Sweden, therefore no trial number is available.


  • Open Access

    Progesterone receptor ( PR ) intra‐tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial

    by Oscar Danielsson, Huma Dar, Gizeh Perez‐Tenorio, Anna Nordenskjöld, Christina Yau, Christopher C. Benz, Laura J. Esserman, Bo Nordenskjöld, Olle Stål, Tommy Fornander, et al.

    Premenopausal breast cancer patients have an increased risk of distant recurrence, but their long‐term risk remains unclear. Notably, over 90% of estrogen receptor (ER) positive tumors in premenopausal patients are also progesterone receptor (PR) positive, compared to 70% in postmenopausal patients. We aimed to determine whether PR intra‐tumor heterogeneity influences long‐term risk of distant recurrence and endocrine therapy benefit in premenopausal breast cancer patients. We conducted a secondary analysis of the Stockholm tamoxifen (STO‐5) randomized controlled trial (1990–1997) with 20‐year complete follow‐up, including 924 premenopausal women with operable breast cancer in Stockholm, Sweden. Patients were randomized to 2 years of adjuvant endocrine therapy or control, with lymph node‐positive patients receiving standard chemotherapy (CMF). Tumor blocks were available for 731 patients. PR intra‐tumor heterogeneity was assessed by measuring variation in PR immunohistochemical staining intensity in whole tumor slides and was categorized as high or low for 520 ER‐positive/PR‐positive patients. Distant recurrence‐free interval (DRFI) by PR heterogeneity was analyzed using Kaplan–Meier, multivariable Cox proportional‐hazards regression, and multivariable time‐varying flexible parametric modeling. We found PR intra‐tumor heterogeneity significantly impacted 20‐year DRFI (log‐rank p = .002). Patients with high intra‐tumor heterogeneity had a significantly increased risk of distant recurrence, compared to patients with low heterogeneity (hazard ratio [HR] = 1.42; 95% CI, 1.02–1.96). Similar results were observed in HER2‐negative patients. Patients with high PR heterogeneity significantly benefited from endocrine therapy (HR = 0.41; 95% CI, 0.24–0.71). These findings suggest that premenopausal patients with high PR heterogeneity have increased long‐term risk but significantly benefit from endocrine therapy.


  • Open Access

    Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

    by Annelie Johansson, Huma Dar, Laura J. van ’t Veer, Nicholas P. Tobin, Gizeh Perez-Tenorio, Anna Nordenskjöld, Ulla Johansson, Johan Hartman, Lambert Skoog, Christina Yau, et al.

    PURPOSE: To assess the long-term (20-year) endocrine therapy benefit in premenopausal patients with breast cancer. METHODS: Secondary analysis of the Stockholm trial (STO-5, 1990-1997) randomly assigning 924 premenopausal patients to 2 years of goserelin (3.6 mg subcutaneously once every 28 days), tamoxifen (40 mg orally once daily), combined goserelin and tamoxifen, or no adjuvant endocrine therapy (control) is performed. Random assignment was stratified by lymph node status; lymph node–positive patients (n = 459) were allocated to standard chemotherapy (cyclophosphamide, methotrexate, and fluorouracil). Primary tumor immunohistochemistry (n = 731) and gene expression profiling (n = 586) were conducted in 2020. The 70-gene signature identified genomic low-risk and high-risk patients. Kaplan-Meier analysis, multivariable Cox proportional hazard regression, and multivariable time-varying flexible parametric modeling assessed the long-term distant recurrence-free interval (DRFI). Swedish high-quality registries allowed a complete follow-up of 20 years. RESULTS: In estrogen receptor–positive patients (n = 584, median age 47 years), goserelin, tamoxifen, and the combination significantly improved long-term distant recurrence-free interval compared with control (multivariable hazard ratio [HR], 0.49; 95% CI, 0.32 to 0.75, HR, 0.57; 95% CI, 0.38 to 0.87, and HR, 0.63; 95% CI, 0.42 to 0.94, respectively). Significant goserelin-tamoxifen interaction was observed ( P = .016). Genomic low-risk patients (n = 305) significantly benefitted from tamoxifen (HR, 0.24; 95% CI, 0.10 to 0.60), and genomic high-risk patients (n = 158) from goserelin (HR, 0.24; 95% CI, 0.10 to 0.54). Increased risk from the addition of tamoxifen to goserelin was seen in genomic high-risk patients (HR, 3.36; 95% CI, 1.39 to 8.07). Moreover, long-lasting 20-year tamoxifen benefit was seen in genomic low-risk patients, whereas genomic high-risk patients had early goserelin benefit. CONCLUSION: This study shows 20-year benefit from 2 years of adjuvant endocrine therapy in estrogen receptor–positive premenopausal patients and suggests differential treatment benefit on the basis of tumor genomic characteristics. Combined goserelin and tamoxifen therapy showed no benefit over single treatment. Long-term follow-up to assess treatment benefit is critical.


  • Open Access

    Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: A cross‐sectional study

    by Jingmei Li, Keith Humphreys, Mikael Eriksson, Huma Dar, Yvonne Brandberg, Per Hall, Kamila Czene

    Literature focusing on health‐related quality of life (HRQoL) by cancer site among women only is scarce. This study examines HRQoL of breast cancer (BC) survivors compared with female survivors of other cancers, and to understand which subgroups of BC survivors were particularly at risk of reduced HRQoL. We placed emphasis on young (n = 242) and female survivors of other cancers (n = 140) with comparable ages at diagnosis (43.6 vs 43.6, p = 0.917) and time since diagnosis (2.3 vs 2.8 years, p < 0.001). HRQoL was assessed using the EORTC QLQ‐C30 questionnaire. While only cognitive functioning was significantly compromised in BC survivors compared with survivors of other cancers when women of all ages were included, young BC survivors reported significantly lower HRQoL on multiple functional scales (global quality of life, emotional, role, social and cognitive functioning) and experienced more fatigue and insomnia. BC survivors with any prior medical history of mental disorders reported poorer HRQoL than those without such a history. We also observed a close–knit relationship between tumor and treatment characteristics. BC survivors perform poorly in HRQoL in comparison with female survivors of other cancers. Our results emphasize the importance of age‐ and gender‐appropriate comparison groups.